All AbMole products are for research use only, cannot be used for human consumption.
LY2835219 mesylate is a potent and selective CDK4/6 dual inhibitor with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4/6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. LY2835219 is being investigated in a phase I clinical trial and in a clinical trial for the treatment of mantle cell lymphoma.
JCI Insight. 2022 Sep 8;7(17):e151851.
Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition
LY2835219 mesylate purchased from AbMole
Cancer Cell. 2018 Sep 10;34(3):411-426.e19.
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
LY2835219 mesylate purchased from AbMole
Sci Rep. 2018 Nov 8;8(1):16579.
Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
LY2835219 mesylate purchased from AbMole
 |
Source | Cancer Cell (2018). Figure 5. abemaciclib (Abmole Bioscience, Houston, USA) |
| Method | oral gavage | |
| Cell Lines | Mice | |
| Concentrations | 50 mg/kg | |
| Incubation Time | — | |
| Results | Mice treated with IRN + VCR had stable disease (SD), whereas mice treated with either palbociclib + trametinib or abemaciclib + trametinib exhibited progressive disease. |
 |
Source | Invest New Drugs (2014). Figure 2. LY2835219 |
| Method | flow cytometry | |
| Cell Lines | MCF10A cells | |
| Concentrations | 5 μM | |
| Incubation Time | 24-hour | |
| Results | LY2835219 induced a G1 arrest in Rb-proficient MDA-MB-231 breast cancer cells, whereas no such effect was seen in Rb-deficient MDA-MB-468 breast cancer cells at compound concentrations up to 2,500 nmol/L |
| Molecular Weight | 602.7 |
| Formula | C27H32F2N8.CH4O3S |
| CAS Number | 1231930-82-7 |
| Solubility (25°C) | Water 90 mg/mL DMSO 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related CDK Products |
|---|
| (E/Z)-Zotiraciclib citrate
(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor. |
| Abemaciclib metabolites M2
Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively. |
| CDK9-IN-1
CDK9-IN-1 is a novel, selective CDK9 inhibitor, with an IC50 of 39 nM for CDK9/CycT1, it can be used for the research of HIV infection. |
| XO44
XO44 (PF-6808472) is a broad-spectrum covalent kinase probe. |
| ML 315
ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
